Characterization of cancer-specific immune responses in MCC may elucidate correlates of anti-PD-1 response/non-responsiveness, and direct us to agents which might be rationally combined with PD-1 inhibition for improved efficacy. This evidence concerns the gene PDCD1 and cancer.